PubRank

David Flockhart

Author PubWeight™ 21.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007 2.32
2 Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2007 1.92
3 A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst 2008 1.45
4 Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy. Menopause 2009 1.24
5 An integrated pharmacokinetics ontology and corpus for text mining. BMC Bioinformatics 2013 1.17
6 Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 2003 1.15
7 The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 2012 1.10
8 CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. Springerplus 2013 0.99
9 Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007 0.97
10 Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics 2007 0.89
11 Antiestrogen pathway (aromatase inhibitor). Pharmacogenet Genomics 2009 0.87
12 Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol 2014 0.83
13 Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans. Ann Intern Med 2004 0.82
14 Patient attitudes toward genotyping in an urban women's health clinic. Obstet Gynecol 2008 0.81
15 Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction. Cancer Prev Res (Phila) 2011 0.81
16 QT analysis: a complex answer to a 'simple' problem. Stat Med 2004 0.79
17 Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. J Clin Pharmacol 2004 0.78
18 Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II. J Psychiatr Pract 2006 0.78
19 A penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotypes. Cancer Inform 2010 0.75
20 Flash points. J Clin Oncol 2007 0.75
21 Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'. Breast Cancer Res Treat 2005 0.75
22 Estimating a positive false discovery rate for variable selection in pharmacogenetic studies. J Biopharm Stat 2007 0.75
23 Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I. J Psychiatr Pract 2006 0.75